Morgan Stanley analyst David Risinger downgraded Teva Pharma (NYSE: TEVA) from Equalweight to Underweight with a price target of $6.00 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE